1. Home
  2. AGMB

as of 03-25-2026 9:48am EST

$12.05
+$0.41
+3.48%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.

Founded: 2017 Country:
Belgium
Belgium
Employees: N/A City: N/A
Market Cap: 677.9M IPO Year: N/A
Target Price: $32.00 AVG Volume (30 days): 115.4K
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $10.50 - $17.45 Next Earning Date: 06-16-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: